In chronic hepatitis C, higher ribavirin (RBV) concentrations are associated with sustained virological response (SVR); target concentration cutoffs have been proposed. As RBV displays interindividual variability, monitoring of RBV plasma levels appears relevant. The impact of RBV therapeutic drug monitoring (TDMRBV) on SVR has not been explored in current practice. Our study aimed to assess this impact.
Methods
Three patient groups were defined as RBV cutoffs achieved at week 12 (group A1), not achieved (group A2), and one without RBV concentration assessment (group B). A predictive model assessed the group impact on SVR in multivariate analysis, while adjusting for additional predictive factors. A specific evaluation of HIV–HCV-coinfected patients was performed.
Results
A total of 122 patients were included. In group A1 (n=30, HIV-positive =18), SVR, relapse and non-response rates were 60%, 17% and 23%, respectively; in group A2 (n=32, HIV-positive =18), 25%, 19% and 56%, respectively; and in group B (n=60, HIV-positive =3), 52%, 33% and 15%, respectively (P=0.0004). The patient group was an independent predictor of SVR (P=0.01), along with baseline viral load and HCV genotype. HIV coinfection did not impede the SVR rate. The cutoffs were achieved in 62% and 28% (P=0.008) of patients, when TDMRBV was performed or not, respectively.
Conclusions
The achievement of RBV cutoffs is a predictive factor of SVR independent of HIV coinfection. It makes it possible to reach high SVR rates, avoid relapse and obtain the same SVR rates in HIV–HCV-coinfected as in HCV-monoinfected patients. TDMRBV enables RBV concentration cutoffs to be reached more frequently and could thus be a useful tool to optimize hepatitis C treatment.
References
1.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
2.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
3.
TorrianiF.J., Rodriguez-TorresM., RockstrohJ.K.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med2004; 351: 438–450.
4.
CarratF., Bani-SadrF., PolS.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA2004; 292: 2839–2848.
5.
McHutchisonJ.G., LawitzE.J., ShiffmanM.L.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med2009; 361: 580–593.
6.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med2004; 140: 346–355.
7.
FriedM.W., JensenD.M., Rodriguez-TorresM.Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology2008; 48: 1033–1043.
8.
GrassoA., MalfattiF., De LeoP.Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol2009; 51: 984–990.
9.
Rodriguez-TorresM., SulkowskiM.S., ChungR.T., HamzehF.M., JensenD.M.Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat2010; 17: 139–147.
10.
RyanP., ResinoS., MirallesP.Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr2010; 55: 176–181.
11.
JenJ.F., GlueP., GuptaS., ZambasD., HajianG.Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit2000; 22: 555–565.
12.
LarratS., Stanke-LabesqueF., PlagesA., ZarskiJ.P., BessardG., SouvignetC.Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother2003; 47: 124–129.
13.
BreilhD., FoucherJ., CasteraL.Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther2009; 30: 487–494.
14.
LindahlK., StahleL., BruchfeldA., SchvarczR.High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology2005; 41: 275–279.
15.
ChanA.H., PartoviN., EnsomM.H.The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C – a critical review. Ann Pharmacother2009; 43: 2044–2063.
16.
MorelloJ., Rodriguez-NovoaS., Jimenez-NacherI., SorianoV.Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother2008; 62: 1174–1180.
17.
MaynardM., PradatP., GagnieuM.C., SouvignetC., TrepoC.Short communication: prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther2008; 13: 607–611.
18.
LabargaP., VispoE., BarreiroP.Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C virus coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr2010; 53: 364–368.
19.
Aguilar MaruccoD., Gonzalez de RequenaD., BonoraS.The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother2008; 61: 919–924.
20.
NicotF., Legrand-AbravanelF., LafontT.Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol2008; 80: 1523–1529.
21.
MorelloJ., SorianoV., BarreiroP.Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother2010; 54: 1647–1649.
22.
Recommendations for professional standards and good epidemiological practices (version France 2007). Rev Epidemiol Sante Publique2008; 56Suppl 1: S121–S148.
23.
D'AvolioA., IbanezA., SciandraM.Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci2006; 835: 127–130.
24.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature2009; 461: 399–401.
25.
ThomasD.L., ThioC.L., MartinM.P.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature2009; 461: 798–801.
26.
PinedaJ.A., CaruzA., RiveroA.Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis2010; 51: 788–795.
27.
RauchA., KutalikZ., DescombesP.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology2010; 138: 1338–1345.
28.
MorelloJ., CuencaL., SorianoV.Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus Infection. J Infect Dis2010; 202: 1185–1191.
29.
FellayJ., ThompsonA.J., GeD.ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature2010; 464: 405–408.
30.
Loustaud-RattiV., AlainS., RousseauA.Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology2008; 47: 1453–1461.
31.
SulkowskiM.S., ShiffmanM.L., AfdhalN.H.HCV treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology2010; 139: 1602–1611.
32.
ChungR.T., AndersenJ., VolberdingP.Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med2004; 351: 451–459.
33.
LagunoM., MurillasJ., BlancoJ.L.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS2004; 18: F27–F36.
34.
TuralC., GalerasJ.A., PlanasR.Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther2008; 13: 1047–1055.
35.
AlbertiA., ClumeckN., CollinsS.Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol2005; 42: 615–624.
